Oncolytics Completes Enrollment for US Phase 2 Study of REOLYSIN in Non-Small Cell Lung Cancer
Oncolytics Biotech (NASDAQ: ONCY) today announced that it has completed patient
enrollment in a Phase 2 clinical trial evaluating intravenous
administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with
non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours (REO 016).
This trial is a single arm, single-stage, open-label, Phase 2 study of
REOLYSIN given intravenously with paclitaxel and carboplatin every
three weeks. Patients received four to six cycles of paclitaxel and
carboplatin in conjunction with REOLYSIN, following which REOLYSIN
could be continued as a monotherapy.
Eligible patients included those with metastatic or recurrent NSCLC with
Kras or EGFR-activated tumours, who had not received chemotherapy treatment
for their metastatic or recurrent disease. Patients must have
demonstrated mutations in Kras or EGFR, or EGFR gene amplification in their tumours (metastatic or
primary) in order to qualify for the trial.
The Company previously reported in November 2012 that 33 patients had
received Reovirus (REOLYSIN) (3 x 1010 TCID50) intravenously daily on days one to five, in combination with
carboplatin and paclitaxel. Molecular tumor demographics included: 16 Kras, three EGFR, four BRAF mutations, and 10 EGFR amplified only. Response
evaluation data reported among 30